TY - GEN
T1 - Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer
T2 - Modern target but ancient solution
AU - Aggarwal, Bharat B.
AU - Sethi, Gautam
AU - Kwang, Seok Ahn
AU - Sandur, Santosh K.
AU - Pandey, Manoj K.
AU - Kunnumakkara, Ajaikumar B.
AU - Sung, Bokyung
AU - Ichikawa, Haruyo
PY - 2006/12
Y1 - 2006/12
N2 - Recent evidence indicates a convergence of molecular targets for both prevention and therapy of cancer. Signal-transducer-and-activator-of- transcription-3 (STAT3), a member of a family of six different transcription factors, is closely linked with tumorigenesis. Its role in cancer is indicated by numerous avenues of evidence, including the following: STAT3 is constitutively active in tumor cells; STAT3 is activated by growth factors (e.g.,EGF, TGF-α, IL-6, hepatocyte growth factor) and oncogenic kinases (e.g., Src); STAT3 regulates the expression of genes that mediate proliferation (e.g., c-myc and cyclin D1), suppress apoptosis (e.g., Bcl-XL and survivin), or promote angiogenesis (e.g, VEGF); STAT3 activation has been linked with chemoresistance and radioresistance; and chemopreventive agents have been shown to suppress STAT3 activation. Thus inhibitors of STAT3 activation have potential for both prevention and therapy of cancer. Besides small peptides and oligonucleotides, numerous small molecules have been identified as blockers of STAT3 activation, including synthetic molecules (e.g., AG 490, decoy peptides, and oligonucleotides) and plant polyphenols (e.g., curcumin, resveratrol, flavopiridol, indirubin, magnolol, piceatannol, parthenolide, EGCG, and cucurbitacin). This article discusses these aspects of STAT3 in more detail.
AB - Recent evidence indicates a convergence of molecular targets for both prevention and therapy of cancer. Signal-transducer-and-activator-of- transcription-3 (STAT3), a member of a family of six different transcription factors, is closely linked with tumorigenesis. Its role in cancer is indicated by numerous avenues of evidence, including the following: STAT3 is constitutively active in tumor cells; STAT3 is activated by growth factors (e.g.,EGF, TGF-α, IL-6, hepatocyte growth factor) and oncogenic kinases (e.g., Src); STAT3 regulates the expression of genes that mediate proliferation (e.g., c-myc and cyclin D1), suppress apoptosis (e.g., Bcl-XL and survivin), or promote angiogenesis (e.g, VEGF); STAT3 activation has been linked with chemoresistance and radioresistance; and chemopreventive agents have been shown to suppress STAT3 activation. Thus inhibitors of STAT3 activation have potential for both prevention and therapy of cancer. Besides small peptides and oligonucleotides, numerous small molecules have been identified as blockers of STAT3 activation, including synthetic molecules (e.g., AG 490, decoy peptides, and oligonucleotides) and plant polyphenols (e.g., curcumin, resveratrol, flavopiridol, indirubin, magnolol, piceatannol, parthenolide, EGCG, and cucurbitacin). This article discusses these aspects of STAT3 in more detail.
UR - http://www.scopus.com/inward/record.url?scp=33947574564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947574564&partnerID=8YFLogxK
U2 - 10.1196/annals.1378.063
DO - 10.1196/annals.1378.063
M3 - Conference contribution
C2 - 17341611
AN - SCOPUS:33947574564
SN - 1573316474
SN - 9781573316477
T3 - Annals of the New York Academy of Sciences
SP - 151
EP - 169
BT - Signal Transduction Pathways, Part B
PB - Blackwell Publishing Inc.
ER -